Amongst sufferers with prostate most cancers with homologous recombination restore mutations (HRRm) receiving Akeega (niraparib) and Zytiga (abiraterone acetate) with prednisone, health-related high quality of life (HR-QOL) remained at baseline, based on patient-reported outcomes (PROs) fromn the AMPLITUDE triql. Findings have been shared on the 2025 ESMO Congress.
With 696 sufferers randomized 1:1 to both the Akeega arm or a placebo arm, at the least 94.3% of sufferers accomplished a web-based questionnaire, which was given to sufferers at screening, throughout cycles 1 to 25, after which each 4 months as much as finish of remedy. The questionnaire used FACT-P, EQ-5D-5L and BPI-SF to measure HR-QOL.
What have been the PROs for sufferers within the AMPLITUDE trial?
Between 76% and 85% of sufferers within the Akeega arm reported through the GP5: Facet Results Hassle single query that they have been “by no means” or “a bit bit” bothered by opposed results (AEs) versus between 86% and 93% within the placebo arm.
FACT-G scores weren’t considerably totally different throughout arms; the general imply LS change from baseline was 0.02 for the Akeega arm and 0.77 for the placebo arm of 0.50 factors. The imply baseline FACT-G rating for the Akeega arm was 79.7 in contrast with 79.3 within the placebo arm.
These scores fluctuated barely, with the Akeega arm’s FACT-G rating reducing between cycles 2 to 4, and the placebo arm’s rating rising at the moment, which lead research creator Dr. Dana Rathkopf, a genitourinary medical oncologist at Memorial Sloan Kettering Most cancers Heart in New York Metropolis, expanded on throughout her presentation of the information.
“You may see that there was an preliminary discount within the HR-QOL rating within the Akeega arm, which can have been defined by the onset of essentially the most continuously noticed opposed occasions, which included hypertension and anemia, which have been subsequently well-managed,” stated Rathkopf. “The rating returned to baseline from cycles 5 and onward.”
Rathkopf additionally famous that the Akeega arm’s FACT-G scores declined towards the top of the trial.
“There was a slight separation of the curves towards the top for the [Akeega] arm,” stated Rathkopf. “This may increasingly have been as a result of there was a better variety of [Akeega] sufferers within the final cycles on research.”
The development that FACT-G scores adopted was echoed throughout most PROs measured.
HR-QOL FACT-P scores remained comparable throughout arms total after following an analogous sample as FACT-G scores within the first 4 cycles. The imply baseline FACT-P rating for the experimental arm was 113.3 and 112.7 within the placebo arm. The general LS imply change from baseline in FACT-P scores was -0.05 within the Akeega arm versus 1.22 within the placebo arm.
Scores on the FACT-P bodily well-being subscale adopted the identical development, with the scores various within the first 4 cycles however remaining comparable total. The imply baseline scores right here have been 23.5 within the Akeega arm and 23.6 within the placebo arm. The general LS imply change from baseline was -0.43 within the experimental arm in contrast with -0.01 within the placebo arm.
EQ-5D-5L Visible Analog Scale scores diverse barely from the sample noticed within the different PROs measured.
“Within the first cycle, there was a slight decline in each the placebo and [Akeega] arms, which returned to baseline for the placebo and returned after cycle 4 to baseline for the [Akeega] arm,” defined Rathkopf.
The imply baseline EQ-RD-5L rating for sufferers within the Akeega arm was 74.9 and 73.9 within the placebo arm. The general LS imply change from baseline was 1.82 and a couple of.59, respectively).
Moreover, time to development as measured by BPI-SF worse ache depth scores was comparable between arms.
What’s the medical significance of the AMPLITUDE trial?
AMPLITUDE, a randomized, double-blind, placebo-controlled part 3 trial, investigated Akeega plus Zytiga and prednisone versus placebo plus Zytiga and prednisone in sufferers with HRR-mutant mHSPC. Each arms additionally obtained androgen deprivation remedy (ADT).
The research met its main finish level of radiographic progression-free survival (rPFS) and located that the Akeega mixture considerably decreased the danger of rPFS by 37% and decreased time to symptomatic development by 50%. The trial discovered the mixture’s security profile to be in keeping with earlier findings.
With a medical knowledge cutoff of Jan. 7, 2025, the median follow-up was 30.8 months, with a median of 25 cycles in each arms.
The present normal of look after this affected person inhabitants is ADT plus an androgen receptor inhibitor with or with out docetaxel.
Reference
- “Affected person (pt) reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled part III trial of niraparib (NIRA) and abiraterone acetate (AA) plus prednisone (P) in metastatic hormone-sensitive prostate most cancers (mHSPC) with homologous recombination restore mutations (HRRm),” by Dr. Dana et al. Introduced at: ESMO 2025 Congress; October 17-21, 2025; Berlin, Germany. Summary LBA91.
